Volume : 10, Issue : 01, January – 2023

Title:

51.A BRIEF REVIEW ON ALZHEIMER’S DISEASE
‬

Authors :

J.S Venkatesh , Dr Santhosh Uttangi, Pooja S Raj* , Ranjini T P*,Rajasree Reghunath *, Reshma Roy*

Abstract :

Alzheimer’s disease is one of the most prevalent dementia that affects nerve cells throughout the brain. This neurodegenerative condition is pathologically brought on by intracellular neurofibrillary tangles and extracellular amyloidal protein, which lead to the development of plaques that impede communication between the nerve cells. Mutations in the APP, PSEN1 and PSEN2 genes have been discovered to be a hereditary risk factor for this condition. Additionally, diet and nutrition have a significant impact on both the progression and prevention of Alzheimer’s disease. Furthermore, using induced pluripotent stemm cells has shown to be a successful method of treating this illness. The goal of this review is to emphasise regarding the stem cell and disease pathogenesis the illness’ therapy.
Key words: Amyloidal protein, dementia, and pluripotent stem cells

Cite This Article:

Please cite this article in press J.S Venkatesh et al, A brief review on Alzheimer’s disease., Indo Am. J. P. Sci, 2023; 10 (01).

Number of Downloads : 10

References:

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, et al. (2013) The global prevalence of dementia: Asystematic review and metaanalysis. Alzheimers Dement 9: 63.e2-75.e2.
2. Gilman S (2010) Oxford American handbook of neurology. Oxford University Press, Oxford, UK.
3. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, et al. (2007) Prevalence of dementia inthe United States: The aging, demographics, and memory study. Neuroepidemiology 29: 125-132.
4. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, et al. (1995) Prevalence ofalzheimer’s disease and vascular dementia: Association with education. The Rotterdam study. BMJ 310: 970-973.
5. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362: 329-344.
6. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298: 789-791.
7. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, et al. (2005) Correlations betweenapolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102: 8299-8302.
8. Sommer I, Griebler U, Kien C, Auer S, Klerings I, et al. (2017) Vitamin D deficiency as a risk factorfor dementia: A systematic review and meta-analysis. BMC Geriatr 17: 16.
9. Gezen-Ak D, Yilmazer S, Dursun E (2014) Why vitamin D in alzheimer’s disease? The hypothesis. JAlzheimers Dis 40: 257-269.
10. Annweiler C, Montero-Odasso M, Hachinski V, Seshadri S, Bartha R, et al. (2013) Vitamin Dconcentration and lateral cerebral ventricle volume in older adults. Mol Nutr Food Res 57: 267-276.
11. Fernandes de Abreu DA, Eyles D, Féron F (2009) Vitamin D, a neuro-immunomodulator:
Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34: S265-S277.
12. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, et al. (2009) 1alpha,25-dihydroxyvitaminD3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of alzheimer’s disease patients. J Alzheimers Dis 17: 703-717.
13. Mizwicki MT, Menegaz D, Zhang J, Barrientos-Durán A, Tse S, et al. (2012) Genomic and nongenomic signaling induced by 1a, 25 (OH) 2-vitamins D3 promotes the recovery of amyloid-b phagocytosis by alzheimer’s disease macrophages. J Alzheimers Dis 29: 51-62.
14. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, et al. (2014) Vitamin D and the risk ofdementia and alzheimer disease. Neurology 83: 920-928.
15. (2015) Alzheimer’s disease genetics fact sheet. National Institute of Aging.
16. Rygiel K (2016) Novel strategies for alzheimer’s disease treatment: An overview of anti-amyloidbeta monoclonal antibodies. Indian J Pharmacol 48: 629-636.
17. Hardy J, De Strooper B (2017) Alzheimer’s disease: Where next for anti-amyloid therapies? Brain140: 853-855.
18. Abbas T, Faivre E, Holscher C (2009) Impairment of synaptic plasticity and memory formation inGLP-1 receptor KO mice: Interaction between type 2 diabetes and alzheimer’s disease. Behav Brain Res 205: 265-271.
19. Agrawal R, Gomez-Pinilla F (2012) Metabolic syndrome’ in the brain: Deficiency in omega-3 fattyacid exacerbates dysfunctions in insulin receptor signalling and cognition. J Physiol 590: 2485-2499.
20. Biessels GJ, Despa F (2018) Cognitive decline and dementia in diabetes mellitus: Mechanisms andclinical implications. Nat Rev Endocrinol 14: 591-604.
21. Das UN (2008) Perinatal and childhood nutrition and its impact on cognitive function and adultdiseases 19.
22. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2011) Deficient brain insulin signaling pathway inalzheimer’s disease and diabetes. J Pathol 225: 54-62.
23. Navrátilová M, Jarkovský J, Cešková E, Leonard B, Sobotka L (2007) Alzheimer disease:Malnutrition and nutrition-al support. Clinical and Experimental Pharmacology and Physiology 34: S11-S13.
24. Nield D (2016) Controlling brain inflammation could slow down the progress of alzheimer’s,scientists find. Science alert.
25. Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, et al. (2008) Transplanted astrocytes internalizedeposited beta-amyloid peptides in a transgenic mouse model of alzheimer’s disease. Glia 56: 154-163.
26. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, et al. (2009) Neural stemcells improve cognition via BDNF in a transgenic model of alzheimer disease. Proc Natl Acad Sci U S A 106: 13594-13599.
27. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. A relationship toaging? Arch Neurol 30: 113-121.
28. Drachman DA, Sahakian BJ (1980) Memory and cognitive function in the elderly. A preliminarytrial of physostigmine. Arch Neurol 37: 674-675.
29. Knusel B, Michel PP, Schwaber JS, Hefti F (1990) Selective and nonselective stimulation of centralcholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci 10: 558-570.
30. Knusel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, et al. (1991) Promotion of centralcholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci USA 88: 961-965.
31. (2018) Alzheimer’s disease: how could stem cells help? EuroStemcell.
32. Humpel C (2011) Identifying and validating biomarkers for alzheimer’s disease. Trends Biotechnol29: 26-32.